Health
New VERTIS-CV data: Kidney function preserved with ertugliflozin in type 2 diabetes – Healio
New exploratory analyses show treatment with the SGLT2 inhibitor ertugliflozin reduced risk for worsening kidney function, dialysis or renal death among adults with type 2 diabetes compared with placebo.In prespecified exploratory analyses presented at the vi…
Source/Disclosures
Source: Cherney D. VERTIS-CV Outcome. Presented at: EASD Annual Meeting; Sept. 21-25, 2020 (virtual meeting).
Disclosures:
Merck and Pfizer sponsored VERTIS-CV. Cannon reports he has received research grants or honoraria from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, Daiichi Sankyo, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer and Sanofi. Cherney reports he has received consultant f…
-
General16 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News22 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General21 hours agoAustralia welcomes Gaza peace progress, hostage release
-
Business24 hours agoBell Potter names the best ASX shares to buy in October